Source: PR Newswire

Press Release: Ablacon : Ablacon Announces Martin Grasse as CEO and Clinical Study Progress

MENLO PARK, Calif., June 22, 2021 /PRNewswire/ -- Ablacon, Inc., developer of an advanced mapping system to guide the treatment of atrial fibrillation (AF), announced today that is has promoted Martin Grasse to the position of Chief Executive Officer. Former CEO Duke Rohlen will continue...

Read full article »

Ablacon's Competitors | Ablacon's News | Ablacon's Financials

Followers on Owler

282

Est. Annual Revenue

$5.0-25M

Est. Employees

25-100

CEO

Martin Grasse

CEO Approval Rating

90/100

Ablacon is a Colorado-based AI firm that designs and develops an atrial fibrillation system to analyze and visualize electrographic flow within the cardiac chambers.